Lineage Cell Therapeutics (LCTX) Minority Interest (2010 - 2026)

Lineage Cell Therapeutics' Minority Interest history runs 17 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, Minority Interest rose 14.06% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 14.06% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 12.13% from the prior year.
• Minority Interest advanced to -$1.2 million in Q1 2026 per LCTX's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Minority Interest topped out at -$1.2 million in Q1 2026 and bottomed at -$1.5 million in Q3 2023.
• The 5-year median for Minority Interest is -$1.4 million (2024), against an average of -$1.4 million.
• Across the five-year window, Minority Interest retreated 24.22% in 2022 and grew 14.06% in 2026, its largest moves.
• Year by year, Minority Interest stood at -$1.4 million in 2022, then rose by 0.5% to -$1.4 million in 2023, then increased by 1.93% to -$1.4 million in 2024, then grew by 12.13% to -$1.2 million in 2025, then grew by 1.91% to -$1.2 million in 2026.
• Per Business Quant, the three latest LCTX Minority Interest figures stand at -$1.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.2 million (Q3 2025).